BioMarin Pharmaceutical | BMRN - Stock


BioMarin Pharmaceutical reported $1.78B in Stock for its fiscal quarter ending in June of 2026.





Stock Change Date
Acadia Pharmaceuticals USD 108.67M 77.1M Jun/2026
Agios Pharmaceuticals USD 35.75M 665K Jun/2026
Alnylam Pharmaceuticals USD 97.11M 103.04M Jun/2026
Amgen USD 6.22B 34M Jun/2026
Bayer EUR 11.97B 43M Jun/2026
Biogen USD 2.38B 435.3M Jun/2026
BioMarin Pharmaceutical USD 1.78B 509.3M Jun/2026
Gilead Sciences USD 1.91B 140M Mar/2026
Incyte USD 112.54M 3.08M Jun/2026
Insmed USD 142.38M 9.48M Jun/2026
Ionis Pharmaceuticals USD 50.83M 45.28M Jun/2026
Moderna USD 280M 134M Jun/2026
Neurocrine Biosciences USD 104.2M 39.7M Jun/2026
PTC Therapeutics USD 91.35M 15.79M Jun/2026
Puma Biotechnology USD 9.48M 885K Sep/2025
Regeneron Pharmaceuticals USD 3.08B 19.3M Jun/2026
Roche Holding CHF 7.6B 9M Jun/2025
Sanofi EUR 23.5B 812M Mar/2026
Sarepta Therapeutics USD 904.27M 96.84M Jun/2026
Ultragenyx Pharmaceutical USD 59M 4M Jun/2026
United Therapeutics USD 193.8M 15.5M Jun/2026
Vertex Pharmaceuticals USD 1.77B 1.6M Jun/2026